Yale School of Medicine

Internal Medicine

Internal Medicine, Yale School of Medicine

Internal Medicine
333 Cedar Street
Room LMP-1072
P.O. Box 208056
New Haven, CT 06520-8056

David A. Fiellin

David A. Fiellin

Associate Professor of Medicine and Investigative Medicine
Section of General Internal Medicine

Research Activities

Dr. Fiellin has focused his scholarly work on the interface between primary care and substance abuse. He conducts research on the transfer of treatment strategies, including opioid agonist maintenance with methadone and buprenorphine, from specialized settings to office-based, primary care and HIV specialty settings. He has directed trials investigating the efficacy of office-based prescribing of methadone and buprenorphine in primary care and HIV specialty settings. He is Co-Principal Investigator on the Veteran’s Aging Cohort Study funded by the National Institute on Alcohol Abuse and Alcoholism, and Co-Investigator on the Health Resources Services Administration’s Buprenorphine in HIV Primary Care National Evaluation Center.

Clinical and Teaching Activities

Investigative Medicine Program

  • Course Co-Director, Principles of Clinical Research
  • Course Co-Director, Seminars in Clinical Investigation

Former Chair, Buprenorphine Training Subcommittee, American Society of Addiction Medicine

Medical Director, SAMHSA Physician Clinical Support System for buprenorphine

Chair, Viral Hepatitis and Substance Abuse Treatment, Center for Substance Abuse Treatment, Treatment Improvement Protocol

Service

He is the Co–Chair of the Society of General Internal Medicine’s Substance Abuse Task Force and recipient of the Nyswander/Dole Award from the American Association for the Treatment of Opioid Dependence and the Annual Award in 2008 from the American Society of Addiction Medicine. He has served on the White House Office of National Drug Control Policy (ONDCP), Drug Control Research, Data, and Evaluation Advisory Committee, and serves on the World Health Organization and United Nations Office on Drugs and Crime Technical Guideline Development Group for psychosocially assisted pharmacologic treatment of opioid dependence. He serves on the Editorial Boards of Substance Abuse and the Journal of Addiction Medicine and is Co-Editor of Alcohol, Other Drugs & Health: Current Evidence and the Principles of Addiction Medicine, 4th Edition.

Selected Publications

  • Fiellin DA, Reid MC, O’Connor PG. New therapies for patients with alcohol problems: Application to primary care. American Journal of Medicine 2000; 108:227-237.
  • O'Connor PG, Fiellin DA. Pharmacologic treatment of heroin-dependent patients. Annals of Internal Medicine 2000; 133: 40-54.
  • Fiellin DA, Reid MC, O'Connor, PG. Screening for alcohol problems in primary care: A systematic review. Archives of Internal Medicine 2000; 160:1977-1989.
  • Fiellin DA, Reid MC, O’Connor PG. Outpatient management of patients with alcohol problems. Annals of Internal Medicine 2000; 133: 815-27.
  • Fiellin DA, O'Connor PG, Chawarski M, Pakes JP, Pantalon MV, Schottenfeld RS. Methadone maintenance in primary care: a randomized controlled trial. JAMA 2001;286:1724-1731.
  • Fiellin DA, O'Connor PG. Office-based treatment of opioid dependent patients. New England Journal of Medicine 2002;347(11):817-823.
  • Fiellin DA, O'Connor PG. New Federal initiatives to enhance the medical treatment of opioid dependence. Annals of Internal Medicine 2002;137:688-692.
  • Sullivan LE, Metzger DS, Fudala PJ, Fiellin DA. Decreasing international HIV transmission: the role of expanding access to opioid agonist therapies for injection drug users. Addiction 2005;100:150-158.
  • Inouye SK, Fiellin DA. An evidence-based guide to writing grant proposals for clinical research. Annals of Internal Medicine 2005;142:274-282.
  • Sullivan LE, Chawarski M, O’Connor PG, Schottenfeld RS, Fiellin DA. The practice of office-based buprenorphine treatment of opioid dependence: Is it associated with new patients entering into treatment? Drug and Alcohol Dependence 2005;79:113-116.
  • Sullivan LE, Fiellin DA. Buprenorphine: its role in preventing HIV transmission and improving the care of HIV infected patients with opioid dependence. Clinical Infectious Diseases 2005;41(6):891-6.
  • Fiellin DA, O’Connor PG, Wang Y, Radford MJ, Krumholz HM. Quality of care for acute myocardial infarction in elderly patients with alcohol-related diagnoses. Alcoholism: Clinical and Experimental Research 2006;30:70-75.
  • Fiellin DA, Pantalon MV, Chawarski MC Moore BA, Sullivan LE, O’Connor PG, Schottenfeld RS. Counseling plus buprenorphine-naloxone maintenance treatment in primary care. New England Journal of Medicine. 2006;355(4):365-374.
  • Mehra R, Moore BA, Crothers K, Tetrault J, Fiellin DA. The association between marijuana smoking and lung cancer: A systematic review. Archives of Internal Medicine 2006;166:1359-1367.
  • Sullivan, LE, Barry D, Moore BA, Chawarski MC, Tetrault JM, Pantalon MV, O’Connor PG, Schottenfeld RS, Fiellin DA. A trial of integrated buprenorphine/naloxone and HIV clinical care. Clinical Infectious Disease 2006;43:S184-S190.
  • Tetrault JM, Crothers K, Moore B, Mehra R, Concato J, Fiellin DA. Effects of marijuana smoking on pulmonary function and respiratory complications: A systematic review. Archives of Internal Medicine 2007;167:221-228.
  • Martell BA, O’Connor PG, Kerns RD, Becker WC, Morales KH, Kosten TR, Fiellin DA. Systematic Review: Opioid treatment for chronic back pain: prevalence, efficacy, and association with addiction. Annals of Internal Medicine 2007;146:116-127.
  • Barry DT, Moore BA, Pantalon MV, Chawarski MC, Sullivan LE, O’Connor PG, Schottenfeld RS, Fiellin DA. Patient satisfaction with primary care office-based buprenorphine/naloxone treatment. Journal of General Internal Medicine 2007;22(2)242-256.
  • Becker WC, Sullivan LE, Tetrault JM, Desai RA, Fiellin DA. Non-medical use, abuse and dependence on prescription opioids among U.S. adults: Psychiatric, medical and substance use correlates. Drug and Alcohol Dependence 2008;94 (1-3):38-47.
  • Sullivan LE, Moore BA, Chawarski MC, Pantalon MV, Barry DT, O’Connor PG, Schottenfeld RS, Fiellin DA. Buprenorphine/naloxone treatment in primary care is associated with decreased HIV risk behaviors. Journal of Substance Abuse Treatment 2008;35:87-92.
  • Sullivan LE, Fiellin DA. Buprenorphine for opioid dependent patients in office practice. Annals of Internal Medicine 2008;148-662-670.
Education:
 Medical school: Emory University School of Medicine, Atlanta, GA
Training:
 Internship/Residency: Yale-New Haven Hospital, New Haven, CT
Chief resident: Yale-New Haven Hospital, New Haven, CT
Postdoctoral Fellow: The Robert Wood Johnson Clinical Scholars Program, Yale University, New Haven, CT

Contact

Campus Address
367 Cedar Street
P.O. Box 208093
New Haven, CT 06520-8093

E-mail
david.fiellin@yale.edu

Office Phone
203-688-2984
Fax 203-737-3306